Virbac stock breaks its 314 € support and loses more than 10% over one month
Animal health is not spared from the deteriorated stock market climate this Wednesday: the security loses ground and crosses an important technical threshold downward. Pressure intensifies over several weeks, in a context where the SBF 120 is also declining during the session.
A 314 € support broken in a dynamic of marked monthly decline
The Virbac stock loses 2.06% during the session, at 309.50 €, after closing the previous day at 316 €. The downward breakthrough of the 314 € support is the notable event of the morning: the security remains below this level, confirming the intraday break. This rupture is part of a decline movement that brings the loss to more than 10% over one month, representing one of the most sustained corrections observed on the security over several months.
The SBF 120 declined by 1.72% during the session, but Virbac's decline exceeds that of the index, which illustrates specific pressure on the security. Ranked 92 out of 120 members within the SBF 120, the value places itself in the lower third of the ranking without being among the largest declines of the day.
Three moving averages above the price, RSI close to oversold
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The technical configuration of Virbac has gradually deteriorated over several weeks. The price is now trading below its three reference moving averages: the MA20 at 327.10 €, the MA50 at 330.56 € and the MA200 at 348.76 €, representing respective gaps of -5.38%, -6.37% and -11.26%. This growing dispersion between the price and its moving averages testifies to a downtrend that has established itself over multiple time horizons.
The RSI at 34 is approaching the oversold threshold at 30, signaling seller exhaustion without reaching it yet. The MACD remains in negative territory, with a histogram at -1.10, reflecting an active bearish dynamic. The next resistance is located at 347.50 €, approximately 12% above the current price, while the absence of an identified intermediate support below 314 € leaves the security without an immediately visible technical floor in the available data.
SectorPharmacie et biotechnologies›Vaccins et laboratoires de recherche
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 9M 2026
Key reported figures
Revenue: 1 168 millions d'euros
Quarterly revenue: 1 168 millions d'euros
Guidance from the release
Notre solide performance à fin septembre 2026 nous permet de viser le haut de notre fourchette initiale de croissance du chiffre d'affaires
Risks mentioned
Effets de change défavorables impactant la croissance réelle (croissance réelle +5,9% vs +7,9% à taux constants)
Pression concurrentielle persistante sur les vaccins porcins en Asie de l'Est et pressions tarifaires au segment Animaux d'élevage
Exposition au Moyen-Orient et suivi des tendances inflationnistes (énergie) malgré anticipation d'impacts limités
Opportunities identified
Croissance soutenue des plateformes Supercharge (+11% environ) couvrant petfood, reproduction, dentaire, mobilité, otologie, endocrinologie et ruminants
Intégration fluide de Thyronorm dans la franchise d'endocrinologie avec contribution de +1 point de croissance et +0,5 point d'Ebit ajusté
Redémarrage réussi de la production du contrat majeur de façonnage en Amérique du Nord (juillet 2026) après contrainte réglementaire temporaire
Outlook / guidance
Expected revenue: 1 575 millions d'euros
Management commentary: « Bien que nos perspectives pour l'ensemble de l'année 2026 restent inchangées, notre solide performance à fin septembre (croissance de +7,9%) nous permet de viser la borne haute de notre fourchette de croissance du chiffre d'affaires de 5,5 % à 7,5 % à PCC »
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.